

Maria Letizia Urban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7819945/publications.pdf>

Version: 2024-02-01

57
papers

1,532
citations

304368

22
h-index

329751

37
g-index

58
all docs

58
docs citations

58
times ranked

1887
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection among patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102575.	2.5	131
2	Changing patterns in clinical and histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1318-1325.	0.5	119
3	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
4	Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. <i>Revue De Medecine Interne</i> , 2015, 36, 15-21.	0.6	71
5	Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	2.9	71
6	Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2143-2151.	2.2	67
7	Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis. <i>Annals of Internal Medicine</i> , 2014, 161, 181.	2.0	64
8	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1898.	1.8	60
9	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
10	Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1584-1586.	0.5	56
11	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	2.9	55
12	Rituximab therapy for chronic periaortitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1262-1264.	0.5	53
13	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 451-455.	1.0	52
14	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1098-1104.	0.5	39
15	Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. <i>PLoS ONE</i> , 2017, 12, e0185880.	1.1	37
16	Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case-control study. <i>Autoimmunity Reviews</i> , 2015, 14, 16-22.	2.5	36
17	Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 446-459.	2.9	36
18	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	0.9	32

#	ARTICLE	IF	CITATIONS
19	Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-211897.	0.5	32
20	Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. <i>Internal and Emergency Medicine</i> , 2017, 12, 727-731.	1.0	29
21	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 2018, 20, 61.	1.3	29
22	Neutrophil-mediated mechanisms of damage and <i>in-vitro</i> protective effect of colchicine in non-vascular Behçet's syndrome. <i>Clinical and Experimental Immunology</i> , 2021, 206, 410-421.	1.1	24
23	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
24	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1670-1680.	2.9	22
25	Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 693.	2.2	22
26	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 433-434.	0.5	19
27	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020, 28, 711-718.	1.9	19
28	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
29	FCγ3-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1597-1599.e8.	1.5	18
30	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1662-1665.	1.5	17
31	Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1913-1922.	2.9	17
32	A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 386-397.	0.5	17
33	Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, e21-e23.	1.6	15
34	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 <i>Medicine</i> , 2021, 85, 68-79.	1.0	14
35	Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. <i>Rheumatology</i> , 2020, 59, 3709-3716.	0.9	12
36	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. <i>Frontiers in Immunology</i> , 2022, 13, 860877.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?. <i>European Journal of Dermatology</i> , 2017, 27, 667-668.	0.3	8
38	Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature. <i>Autoimmunity Reviews</i> , 2020, 19, 102620.	2.5	8
39	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2020, 59, 3563-3566.	0.9	8
40	Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 189-199.	2.3	7
41	Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1357-1367.	1.0	7
42	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 47-50.	0.4	7
43	Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience. <i>Dermatologic Therapy</i> , 2018, 31, e12675.	0.8	6
44	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 47-50.	0.4	4
45	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
46	Treatment of idiopathic retroperitoneal fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 769-777.	0.5	1
47	SP137PERSISTENT REDUCTION OF SERUM C3 AND LUPUS NEPHRITIS OUTCOME: A RETROSPECTIVE OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii422-iii423.	0.4	1
48	FRI0199...EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY. , 2019, , .		1
49	MP204SLOWLY PROGRESSIVE GLOMERULONEPHRITIS IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS (AAV). <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii502-iii503.	0.4	0
50	Sa0020RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i323-i323.	0.4	0
51	FP165SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
52	298.â€fRITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PERIAORTITIS: A CASE-SERIES OF 20 PATIENTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
53	135.â€fATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
54	117.â€fPREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURGâ€“ STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
55	P0181 PERSISTENT C3 HYPOCOMPLEMENTEMIA AND MODERATE TUBULOINTERSTITIAL SCARRING AS EARLY PREDICTORS OF END-STAGE RENAL DISEASE IN LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
56	P0280 ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
57	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	1.8	0